Nonprofit product advancement partnerships.

Mohrle, Medications for Malaria Venture, Geneva, SwitzerlandExtending a Hands: Eli Lilly’s TB Medication Discovery Partnership – – Gail H. Cassell, Eli Lilly & Co., Indianapolis, INRelated StoriesResearchers make use of cutting edge genomic methods to explain protective effects of malaria vaccine candidateCombatting viral and bacterial lung infections with volatile anesthetics: an interview with Dr ChakravarthyTGen researchers join international scientists in discovering how malaria protein could some day help stop cancerThe goal of the symposium was to illustrate how market/community sector collaborations help bridge what Dr. Earl calls an invention gap for new remedies for infectious diseases of poverty. Historically, most global health products lacked a profitable market that would justify investing the millions of dollars had a need to develop new medicines, he described.‘This new program, with its inspiring, personal stories of symptoms, struggles and effective treatment, lends a voice to the once taboo topic and additional demonstrates the AMS dedication to support ladies facing pelvic health issues like SUI.’ The 30-minute system profiles three women who suffered from SUI and features medical experts who define this common condition and discuss choices for treating and controlling it.

Agios Pharmaceuticals presents data on cancer-associated IDH1 mutations in 101st AACR meeting Agios Pharmaceuticals, a biopharmaceutical business focused on discovering and developing novel medications in the field of cancer metabolism, today announced multiple presentations in the American Association for Cancer Research 101st Annual Meeting that highlight cancer metabolism as an approach to identify new methods to treat cancer, starting the potential for a fresh class of cancer medicines targeting metabolic enzymes.